Grammidin with anesthetic Neo lozenges №9×2

Name:
Grammidin with anesthetic Neo tab. dras. in a box No. 9х2
Description:
Tablets of white color, round, biconvex, with an inscription on one party GR. Composition 1 tablet contains: Active substances: gramicidin C – 3.00 mg (in the form of gramicidin C dihydrochloride – 3.20 mg), oxybuprocaine hydrochloride – 0.20 mg, cetylpyridinium chloride – 1.00 mg (in the form of cetylpyridinium chloride monohydrate – 1 .05 mg). Excipients: colloidal silicon dioxide – 5.00 mg, talc – 60.00 mg, acesulfame potassium – 15.00 mg, mint flavor – 25.00 mg, sorbitol – 1065.55 mg, magnesium stearate – 25.00 mg. Pharmacotherapeutic groupMeans for the treatment of diseases of the larynx and pharynx. Other antiseptics. ATX code: R02AA20. Pharmacological properties Pharmacodynamics Combined drug for the treatment of infectious and inflammatory diseases of the pharynx and oral cavity. The composition of the drug includes the antimicrobial agent gramicidin C, the antiseptic agent – cetylpyridinium chloride and the local anesthetic (pain reliever) agent – oxybuprocaine. The mechanism of action of gramicidin C is associated with an increase in the permeability of the cytoplasmic membrane of a microbial cell, which disrupts its stability and causes cell death. Cetylpyridinium chloride is an antiseptic from the group of quaternary ammonium compounds, has antimicrobial and antifungal (Candida albicans) action, does not affect mycobacteria. The anesthetic oxybuprocaine has a local anesthetic effect on the mucous membrane of the mouth and throat. It causes a reversible blockade of the propagation and conduction of nerve impulses through the axons of nerve cells. The drug has an antimicrobial effect, helps to reduce pain. Pharmacokinetics The drug has a local effect and is practically not absorbed in the gastrointestinal tract. Indications for use Local symptomatic treatment of infectious and inflammatory diseases of the oral cavity and pharynx. Dosage and administration It is used after meals, by resorption in the mouth without chewing. Immediately after using the drug, you should refrain from eating and drinking for 1-2 hours. Dosage for adults and children over 12 years old: 1 tablet 3-4 times a day. Dosage for children from 6 to 12 years old: 1 tablet 1-2 times a day. The drug should not be taken for more than 7 days. If you need a longer use or the absence of a therapeutic effect (including in case of deterioration), it is recommended to consult a doctor. Side effectsThe frequency of adverse reactions is determined using the following scale: very often (> 1/10), often (> 1/100 to <1/10), infrequently (> 1/1000 to <1/100), rarely (> 1/10 10000 <1/1000), very rare (<1/10000), not known (frequency cannot be estimated based on available data). Rare: allergic reactions, change in taste, irritation of the oral mucosa, delayed healing of wounds of the oral mucosa. Frequency not known: Nausea, vomiting, temporary loss of sensation of the tongue and oral mucosa. In case of adverse reactions, including those not listed in this leaflet, you should consult a doctor. Contraindications hypersensitivity to the components that make up the drug; children under 6 years of age; pregnancy. Overdose There is no information on cases of overdose. Given the amount of active and excipients contained in 1 tablet, the possibility of an overdose is minimal. Symptoms when the recommended doses for cetylpyridinium chloride are exceeded are gastrointestinal disorders (nausea, vomiting, diarrhea). Sorbitol, which is part of the drug, with a significant overdose (more than 30 g of sorbitol per day) can cause diarrhea, flatulence. Systemic effects in case of an overdose of oxybuprocaine may be accompanied by the development of agitation, irritability, asthenia, drowsiness, dizziness, tremor, nausea, vomiting, respiratory failure, bradycardia, atrioventricular blockade, in severe cases, convulsions, cardiac arrest, coma. In case of overdose, you should consult a doctor. Treatment: drug withdrawal, gastric lavage, symptomatic therapy. Precautions If during the use of the drug the symptoms of the disease persist or worsen (fever rises, cough, headache, vomiting, etc.) you should consult a doctor. In case of bacterial infections, in particular those caused by streptococcus, it is recommended to prescribe the main etiotropic therapy with an appropriate antibacterial agent of systemic action. With the development of a viral infection, the use of the drug as a monotherapy may not be effective enough, since the viral infection develops intracellularly. It is not recommended to use cetylpyridinium chloride in case of damage to the mucous membrane due to the possible inhibition of repair processes. Patients with contact allergies should not take the drug, as the likelihood of sensitization increases. The use of the drug may temporarily change the taste sensations, but within 4 hours after taking the drug, taste perception is restored. It is recommended to take the drug after meals. For some dosage forms of drugs containing cetylpyridinium chloride, it has been shown that their long-term use can cause a slight temporary brown staining of the teeth and tongue, but these phenomena disappear after the drug is discontinued. Due to the content of sorbitol, the drug is not recommended for patients with congenital fructose intolerance. Due to the content of sorbitol, the drug may have a slight laxative effect. Local anesthetics can interfere with the normal coordination of the swallowing reflex, increasing the risk of aspiration of food and water. In this regard, it is not recommended to eat or drink immediately after taking the tablet. Numbness of the tongue and oral mucosa, which can occur with the use of local anesthetics, may increase the risk of injury to the mucosa and tongue from biting. Use in children: Do not use in children under 6 years of age due to the risk of accidental inhalation and aspiration of the tablet. Use during pregnancy and lactation The drug is contraindicated during pregnancy due to lack of sufficient data. There are no data on the penetration of active ingredients into breast milk. The drug is not recommended during breastfeeding. Interaction with other drugs The activity of cetylpyridinium chloride decreases when it is inactivated by protein and lipid components in the focus of inflammation. Influence on the ability to drive vehicles and work with mechanisms Studies to assess the effect of the drug on the reaction rate have not been conducted. Based on the profile of adverse reactions, the effect of the drug on the ability to drive a car and work with mechanisms is not expected. Conditions and shelf life In a place protected from light and moisture at a temperature not exceeding 25 ° C. Keep out of the reach of children. Shelf life 2 years. Do not use after the expiration date. Holiday conditions Without a prescription. Packing: 9 tablets in a blister pack with perforation made of PVC or PVC/PVC film and printed lacquered aluminum foil. 2 contour packs, together with instructions for use, are placed in a cardboard box. Buy Grammidin with anesthetic Neo lozenges No. 9x2 The price of Grammidin with anesthetic Neo lozenges No. 9x2